MA-ICURE-PHARMACEUTICAL
16.11.2021 15:03:14 CET | Business Wire | Press release
Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.
The drug product approval process took 7 months after it filed an application in April 2021. With the approval, Icure marks the first commercialization of the donepezil patch in the world.
Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments. Due to difficulty in the development of its formulations, donepezil has been commercialized for only oral administration to date.
With successful completion of a Phase III clinical trial for the first time in the world, the donepezil patch of Icure is expected to significantly improve the quality of life of patients with Alzheimer’s-type dementia and their caregivers by enhancing the convenience in its use from orally taking once daily to putting a patch on skin twice a week.
With nearly 400 mild and moderate dementia patients in Korea, Taiwan, Australia and Malaysia, Icure successfully conducted a Phase III clinical study for its donepezil patch. Specifically, the study demonstrated noninferiority compared to oral donepezil in Alzheimer's disease assessment scale cognitive subscale (ADAS-cog), a typical standard tool for evaluating abilities of memory, language, reorganization, action and orientation in patients with mild and moderate Alzheimer’s-type dementia.
“Based on outstanding efficacy and marketability of donepezil along with our technological prowess, we expect our donepezil patch will sufficiently take over the market of donepezil oral products as we have seen a high conversion rate of rivastigmine patches in the past,” said CEO YoungKweon Choi, Ph.D. of Icure, who led donepezil patch development. “We reported results of the Phase III clinical trial of donepezil patch at the Conference on Clinical Trials of Alzheimer’s Disease (CTAD) that was held on November 9~12, 2021 in Boston, Massachusetts.” He attended the CTAD Conference to present the results of the clinical study while making consultations on potential global transactions.
Now that its donepezil patch received FDA approval for Phase I clinical trial as an investigational new drug in April 2021, Icure will start to administer it to patients in the latter part of 2022. The company expects to begin in 2025 to provide the donepezil patch in the global market by reducing the period of clinical trials through the 505(b)2 clinical study track. Today, the global dementia treatments market is estimated to reach around USD 3 billion, and it is anticipated to increase to roughly USD 5 billion by 2024 as the world transforms into an aging society. Icure plans to expand the global business of transdermal drug delivery system (TDDS) as its production facilities in Wanju, Korea obtained the cGMP certification.
Starting with the donepezil patch, Icure diversifies pipelines by developing a variety of DDS-based incrementally modified drugs and new drugs. Following the donepezil patch, the company is developing a pramipexole patch that will be used for treating Parkinson’s disease. And Icure BNP, a subsidiary of Icure, is currently developing oral liraglutide peptide formulation from injectable liraglutide peptide product that is being used for treating diabetes and obesity while accelerating the development of microneedles and lipid-based nanoparticle (LNP) drugs through CuRsuS Bio and EBA BIO. In addition, Icure is also in the development of the world’s first oral peptide-based anticancer drug and a new drug based on PROTAC through oneCureGen and Dandi Cure, attracting attention on the potentiality of growing into a global pharmaceutical company by developing varied DDS-based new drugs.
For more information on Icure Pharmaceutical Inc., visit https://icure.co.kr .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005684/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
du and Comarch Communications Launch Agentic AI for OSS Network Operations28.10.2026 13:00:00 CET | Press release
du, the leading telecommunications and digital service provider and Comarch Communications, a global provider of Enterprise Tech solutions for connectivity, have expanded their partnership to lay the data foundation for goal-oriented autonomous execution. Comarch Communications is delivering a major upgrade to du’s Operational Support Systems (OSS) platform. By creating a unified central hub for all network data regardless of its source, the platform automatically keeps information up to date, giving du complete real-time visibility over its network resources. Justin Shields, CIO at du: “Our ambition at du is to raise the standard for operational agility while keeping the trust of our customers. Resilience and control are at the center of how we plan to scale AI. This next phase with Comarch Communications strengthens the inventory and topology foundation that underpins our vision for an enhanced customer experience, while enabling a new generation of AI-driven applications and workflo
Patsnap Launches AI Agents to Extract SAR Data and Identify Lead Compounds From Small Molecule Patents28.10.2026 13:00:00 CET | Press release
Lead Compound Analyzer and SAR Extractor help scientists identify likely lead compounds and turn patent-disclosed chemistry into structured, source-referenced data for drug discovery. Patsnap today announced Lead Compound Analyzer and SAR Extractor, two AI agents in Patsnap Eureka Life Sciences that help drug discovery teams identify likely lead compounds and extract structure-activity data from small molecule patents. By reducing manual extraction, the agents help medicinal chemistry, competitive intelligence and computational teams assess competitor compounds, compare chemical series and inform further research. Learn more here. AI is giving drug discovery teams new ways to analyze compounds and guide molecular design, but those workflows depend on the experimental data available to them. Patents are often an early public source of new compounds, potency data and structure-activity relationships, yet that evidence remains difficult to reuse. Compound structures appear as images, acti
NIQ Expands Shopper Experience Platform to Improve Product Discovery in AI-Powered Shopping28.10.2026 12:00:00 CET | Press release
New optimization capabilities and NIQ’s CONTENT Framework help brands strengthen product visibility, relevance and performance across retail and AI-powered shopping channels NielsenIQ (NYSE: NIQ)today announced new optimization capabilities for its Shopper Experience Platform, supported by its CONTENT Framework, a seven-pillar approach to evaluating and improving product content. Together, they enable brands to evaluate product content and imagery against retailer requirements and category expectations, identify gaps, and prioritize improvements that strengthen product discovery across retailer sites, search engines, and AI-powered shopping channels. A product can be accurate, complete, and retailer-compliant yet still be difficult for shoppers to find, understand, or choose. This challenge is growing as AI assistants, retailer algorithms, and recommendation engines play a larger role in shopping. According to NIQ's Consumer Outlook: Guide to 2027, 55% of global consumers report having
Tula Technology Signs Landmark Agreement Licensing Dynamic Motor Drive® to Global Tier 1 Supplier28.10.2026 12:00:00 CET | Press release
Agreement covers supplier’s full E-drive portfolio, creating global production opportunities Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today announced that it has signed an intellectual property license agreement with a global Tier 1 automotive supplier covering the supplier’s entire E-drive portfolio. Under the agreement, the Tier 1 supplier has a non-exclusive license to Tula’s DMD portfolio of patents covering the U.S., Europe, and Asia. The agreement marks the first commercial deployment of DMD spanning the supplier's complete E‑drive portfolio. DMD is an innovative software‑only technology that strategically applies torque pulses under optimal conditions, reducing drive‑cycle energy consumption by 0.5‑2.0%. Because DMD is implemented entirely in software, it requires no hardware changes or additions, allowing suppliers and OEMs to integrate the technology into existing E‑drive systems with minimal engineering effort. The
PayNet Enables Malaysian Mobile Banking App Users to Make Overseas DuitNow QR Payments via Alipay+28.10.2026 11:42:00 CET | Press release
Malaysians can now pay using supported local banking apps in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. More markets will be added progressively. Payments Network Malaysia Sdn Bhd (PayNet) today announced the launch of outbound DuitNow QR payment connectivity through Alipay+, the unified wallet gateway of Ant International. Malaysians can now use supported local mobile banking apps to pay at participating Alipay+-supported merchants in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. The initial three launch banks are Maybank, CIMB and Hong Leong Bank, with Bank Islam set to join soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028063575/en/ From left to right: Michael Guo, General Manager of Alipay+ SEA, ANZ and South Asia, Ant International; Praveen Rajan, Chief Executive Officer of PayNet; Danny Chung, General Manager of Alipa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom